Factor VII, tissue factor pathway inhibitor, and monocyte tissue factor in diabetes mellitus: influence of type of diabetes, obesity index, and age.
Changes of the tissue factor (TF) pathway of blood coagulation have been described in diabetes and could be involved in its vascular complications. In order to evaluate the influence of the type of diabetes and of the obesity index and age on these changes, factor VII coagulant activity, factor VII antigen, activated factor VII, monocyte TF expression, and plasma Tissue Factor Pathway Inhibitor (TFPI) were examined in 18 Type 1 and 16 Type 2 diabetic patients compared to non-diabetic control subjects matched for age, sex, and obesity index (Types 1 and 2 controls, respectively). Multicomplicated patients were excluded. FVIIc, FVIIAg, and FVIIa were higher in Type 2 diabetic patients and controls than in Type 1 diabetic patients and controls (P< .03). However, FVIIc and FVIIAg were lower in diabetic patients than in their matched controls (P< .03). Monocyte expression of TF was not different between Types 1 and 2 diabetic patients and their matched controls except for LPS-stimulated monocyte TF activity which was lower in Type 2 diabetic patients than in Type 2 controls (P< .05). Plasma TFPI was slightly but significantly higher in Type 1 diabetic patients than in Type 1 controls (P= .01) and was correlated to glycemia. However, both in Type 2 diabetic patients and controls, TFPI was higher than in Type 1 controls and was correlated with BMI (P< .0003). These results indicate that in not multicomplicated patients, the increase of FVII and TFPI was highly dependent on obesity index and age rather than on diabetes by itself.
Vambergue
A
A
Department of Endocrinology and Diabetology, Clinique Marc Linquette, CHRU, Lille, France.
Rugeri
L
L
Gaveriaux
V
V
Devos
P
P
Martin
A
A
Fermon
C
C
Fontaine
P
P
Jude
B
B
D000328:Adult; D000367:Age Factors; D000941:Antigens / Q000032:analysis; D001053:Apolipoproteins / Q000097:blood; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003920:Diabetes Mellitus / Q000097:blood* / Q000503:physiopathology; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000503:physiopathology; D005167:Factor VII / Q000032:analysis*; D065427:Factor Xa Inhibitors; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000502:physiology; D009765:Obesity; D012016:Reference Values; D013925:Thromboplastin / Q000032:analysis*
D000941:Antigens; D001053:Apolipoproteins; D002784:Cholesterol; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D005167:Factor VII; D065427:Factor Xa Inhibitors; D006442:Glycated Hemoglobin; D008074:Lipoproteins; D013925:Thromboplastin; C042580:factor VII clotting antigen; C051928:lipoprotein-associated coagulation inhibitor